Skip to main content

Eledon Pharmaceuticals, Inc. (ELDN)

NASDAQ: ELDN · IEX Real-Time Price · USD
6.79 -0.11 (-1.59%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap95.85M
Revenue (ttm)n/a
Net Income (ttm)-27.93M
Shares Out14.82M
EPS (ttm)-3.33
PE Ration/a
Forward PE4.64
Dividendn/a
Ex-Dividend Daten/a
Volume51,312
Open6.77
Previous Close6.90
Day's Range6.56 - 6.85
52-Week Range5.91 - 27.32
Beta2.00
AnalystsStrong Buy
Price Target30.80 (+353.6%)
Est. Earnings DateNov 15, 2021

About ELDN

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the trea...

IndustryBiotechnology
Founded2004
CEOGregory Flesher
Employees10
Stock ExchangeNASDAQ
Ticker SymbolELDN
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ELDN stock is "Strong Buy." The 12-month stock price forecast is 30.80, which is an increase of 353.61% from the latest price.

Price Target
$30.80
(353.61% upside)
Analyst Consensus: Strong Buy

News

Eledon Pharmaceuticals to Present at Two Investor Conferences in September

IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons...

3 weeks ago - GlobeNewsWire

A Duo of Net Current Asset Value Stock Picks to Consider

There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can get a huge return out of these stocks after the market has reasses...

Other symbols:RWLK
1 month ago - GuruFocus

Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results

Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial in Q4 with initial data in late 2022

1 month ago - GlobeNewsWire

Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

1 month ago - GlobeNewsWire

Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transpl...

Interim data expected in late 2022 in a multicenter, open label study to replace tacrolimus with AT-1501

1 month ago - GlobeNewsWire

Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors

IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...

2 months ago - GlobeNewsWire

Eledon Pharmaceuticals to Present at the Virtual Ladenburg Thalmann Healthcare Conference

IRVINE, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons ...

2 months ago - GlobeNewsWire

Eledon Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference

IRVINE, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons l...

4 months ago - GlobeNewsWire

Eledon Pharmaceuticals Reports First Quarter 2021 Operating and Financial Results

Continued enrollment in Phase 2 clinical trial of AT-1501 in amyotrophic lateral sclerosis (ALS)

4 months ago - GlobeNewsWire

Eledon Pharmaceuticals Announces Upcoming Presentations on AT-1501 at the Virtual 2021 American Transplant Congress

IRVINE, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons l...

4 months ago - GlobeNewsWire

Eledon Pharmaceuticals to Release First Quarter Financial Results on Thursday, May 13, 2021

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

4 months ago - GlobeNewsWire

Eledon Pharma Stock Jumps Despite FDA Asking For Additional Preclinical Study In Non-Primate Animal Models

As part of ongoing discussions with the FDA regarding Eledon Pharmaceuticals Inc's (NASDAQ: ELDN) AT-1501 renal transplant program, the agency has requested AT-1501 specific renal transplant data in non...

4 months ago - Benzinga

Eledon Pharmaceuticals Announces Update on Development Strategy for AT-1501 in Renal Transplantation

IRVINE, Calif., April 26, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons...

4 months ago - GlobeNewsWire

Moving Average Crossover Alert: Eledon Pharma (ELDN)

Eledon Pharmaceuticals (ELDN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

5 months ago - Zacks Investment Research

Eledon Pharmaceuticals Continues to Bolster Leadership Team with Addition of Two More Key Executives

David Hovland, Ph.D., to serve as Chief Regulatory Officer and Bryan Smith, J.D. as General Counsel, Corporate Secretary, and Chief Compliance Officer David Hovland, Ph.D., to serve as Chief Regulatory ...

5 months ago - GlobeNewsWire

Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Operating and Financial Results

Continued enrollment in Phase 2 clinical trial of AT-1501 in amyotrophic lateral sclerosis (ALS)

5 months ago - GlobeNewsWire

Eledon Pharmaceuticals to Release Fourth Quarter and Full-Year Financial Results on Tuesday, March 30

Management to host conference call and webcast at 4:30 pm ET Management to host conference call and webcast at 4:30 pm ET

6 months ago - GlobeNewsWire

Novus Therapeutics Announces Name Change to Eledon Pharmaceuticals; Provides Corporate Update and Outlook

Eledon to commence trading on the Nasdaq exchange under the ticker “ELDN” effective tomorrow, January 5, 2021

8 months ago - GlobeNewsWire

Novus Therapeutics Appoints June Lee, M.D., to Board of Directors

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics announced the appointment of June Lee, M.D., to the company's Board of Directors.

9 months ago - Business Wire

Novus Therapeutics, Inc. (NVUS) CEO David-Alexandre Gros on Q3 2020 Results - Earnings Call Transcript

Novus Therapeutics, Inc. (NVUS) CEO David-Alexandre Gros on Q3 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Novus Therapeutics Reports Third Quarter 2020 Financial Results

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients underg...

10 months ago - Business Wire

Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients underg...

10 months ago - Business Wire

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyo...

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

10 months ago - Business Wire

Moving Average Crossover Alert: Novus Therapeutics

Novus Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

11 months ago - Zacks Investment Research

Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces One-for-Eighteen Reverse Stock Split

11 months ago - Business Wire